NEW YORK – Personalis said today that it has entered into a research agreement with biopharmaceutical firm Invectys, under which it will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia patients participating in a clinical trial.